Accolade logo

Accolade share price today

(ACCD)

Accolade share price is $3.49 & ₹295.82 as on 14 Dec 2024, 2.30 'hrs' IST

$3.49

▲

0.01

(0.29%)

Market is closed - opens 8 PM, 16 Dec 2024

View live Accolade share price in Dollar and Rupees. Guide to invest in Accolade from India. Also see the sentimental analysis on Indian investors investing in Accolade. Get details on the Indian mutual funds that are investing in Accolade. Get Analyst recommendations and forecasts along with all the Accolade's financials.

Accolade share price movements

  • $3.41
    $3.52

    Day's Volatility :2.99%

  • $3.08
    $15.36

    52 Weeks Volatility :79.95%

Accolade Returns

PeriodAccolade IncSector (Health Care)Index (Russel 2000)
3 Months
-17.34%
-9.7%
0.0%
6 Months
-43.78%
-3.4%
0.0%
1 Year
-66.79%
3.7%
0.0%
3 Years
-85.57%
3.8%
-18.9%

Accolade Key Statistics

in dollars & INR

Previous Close
$3.48
Open
$3.47
Today's High
$3.515
Today's Low
$3.41
Market Capitalization
$294.8M
Today's Volume
$576.4K
52 Week High
$15.36
52 Week Low
$3.08
Revenue TTM
$441.0M
EBITDA
$-53.6M
Earnings Per Share (EPS)
$-1.02
Profit Margin
-18.16%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-18.61%

How to invest in Accolade from India?

It is very easy for Indian residents to invest directly in Accolade from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Accolade stock in both rupees (INR) and dollars (USD). Search for Accolade or ACCD on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Accolade or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Accolade shares which would translate to 0.243 fractional shares of Accolade as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Accolade

-76%

Period: Sep 14, 2024 to Dec 13, 2024. Change in 30 Days versus previous period

Search volume for Accolade on INDmoney from India has reduced in the last 30 days as on Dec 14, 2024. -76% less investors are searching Accolade in the last 30 days versus the previous period.

Global Institutional Holdings in Accolade

  • BlackRock Inc

    7.65%

  • ARK Investment Management LLC

    6.68%

  • Brown Advisory Holdings Inc

    5.99%

  • Vanguard Group Inc

    5.16%

  • Millennium Management LLC

    4.95%

  • Deerfield Management Co

    4.31%

Analyst Recommendation on Accolade

Buy

    69%Buy

    30%Hold

    0%Sell

Based on 23 Wall street analysts offering stock ratings for Accolade(by analysts ranked 0 to 5 stars)

Based on 23 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
15
Hold
7
7
7
Sell
0
0
0

Analyst Forecast on Accolade

What analysts predicted

Upside of 107.95%

Current:

$3.49

Target:

$7.26

Insights on Accolade

  • Price Movement

    In the last 6 months, ACCD stock has moved down by -46.0%

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 124.83M → 106.36M (in $), with an average decrease of 7.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -27.59M → -23.93M (in $), with an average increase of 15.3% per quarter

  • ACCD vs DOCS (1 yr)

    In the last 1 year, Doximity, Inc. has given 113.7% return, outperforming this stock by 179.6%

  • ACCD vs DOCS (3 yr)

    In the last 3 years, Accolade Inc has experienced a drawdown of -85.2%, however Doximity, Inc. resisted the overall trend and outperformed by 79.8%

  • Price to Sales

    ForACCD every $1 of sales, investors are willing to pay $0.6, whereas for Doximity, Inc., the investors are paying $19.0 for every $1 of sales.

Accolade Financials in INR & Dollars

FY19Y/Y Change
Revenue
$94.8M
↑ 23.41%
Net Income
$-56.5M
↓ 7.82%
Net Profit Margin
-59.59%
↑ 20.18%
FY20Y/Y Change
Revenue
$132.5M
↑ 39.76%
Net Income
$-51.4M
↓ 9.08%
Net Profit Margin
-38.76%
↑ 20.83%
FY21Y/Y Change
Revenue
$170.4M
↑ 28.57%
Net Income
$-50.7M
↓ 1.39%
Net Profit Margin
-29.73%
↑ 9.03%
FY22Y/Y Change
Revenue
$310.0M
↑ 81.98%
Net Income
$-123.1M
↑ 143.08%
Net Profit Margin
-39.71%
↓ 9.98%
FY23Y/Y Change
Revenue
$363.1M
↑ 17.13%
Net Income
$-459.7M
↑ 273.32%
Net Profit Margin
-126.58%
↓ 86.87%
FY24Y/Y Change
Revenue
$414.3M
↑ 14.09%
Net Income
$-99.8M
↓ 78.29%
Net Profit Margin
-24.09%
↑ 102.49%
Q2 FY23Q/Q Change
Revenue
$93.2M
↓ 5.86%
Net Income
$-38.4M
↑ 26.21%
Net Profit Margin
-41.2%
↓ 10.47%
Q3 FY23Q/Q Change
Revenue
$96.9M
↑ 3.9%
Net Income
$-32.8M
↓ 14.54%
Net Profit Margin
-33.89%
↑ 7.31%
Q4 FY23Q/Q Change
Revenue
$99.4M
↑ 2.59%
Net Income
$-21.1M
↓ 35.83%
Net Profit Margin
-21.2%
↑ 12.69%
Q1 FY24Q/Q Change
Revenue
$124.8M
↑ 25.62%
Net Income
$-7.5M
↓ 64.36%
Net Profit Margin
-6.01%
↑ 15.19%
Q2 FY24Q/Q Change
Revenue
$110.5M
↓ 11.51%
Net Income
$-27.6M
↑ 267.55%
Net Profit Margin
-24.98%
↓ 18.97%
Q3 FY24Q/Q Change
Revenue
$106.4M
↓ 3.72%
Net Income
$-23.9M
↓ 13.26%
Net Profit Margin
-22.5%
↑ 2.48%
FY19Y/Y Change
Profit
$34.2M
↑ 46.38%
FY20Y/Y Change
Profit
$58.8M
↑ 71.78%
FY21Y/Y Change
Profit
$76.7M
↑ 30.37%
FY22Y/Y Change
Profit
$141.0M
↑ 83.87%
FY23Y/Y Change
Profit
$164.2M
↑ 16.48%
FY24Y/Y Change
Profit
$192.1M
↑ 16.94%
Q2 FY23Q/Q Change
Profit
$39.0M
↓ 18.66%
Q3 FY23Q/Q Change
Profit
$41.5M
↑ 6.47%
Q4 FY23Q/Q Change
Profit
$44.9M
↑ 7.96%
Q1 FY24Q/Q Change
Profit
$54.3M
↑ 21.12%
Q2 FY24Q/Q Change
Profit
$41.5M
↓ 23.68%
Q3 FY24Q/Q Change
Profit
$49.4M
↑ 19.23%
FY19Y/Y Change
Operating Cash Flow
$-16.5M
↓ 56.78%
Investing Cash Flow
$-3.1M
↓ 56.41%
Financing Cash Flow
$48.8M
↑ 224.71%
FY20Y/Y Change
Operating Cash Flow
$-34.2M
↑ 106.96%
Investing Cash Flow
$-3.5M
↑ 12.92%
Financing Cash Flow
$28.2M
↓ 42.21%
FY21Y/Y Change
Operating Cash Flow
$-25.2M
↓ 26.32%
Investing Cash Flow
$-2.4M
↓ 31.18%
Financing Cash Flow
$428.4M
↑ 1417.91%
FY22Y/Y Change
Operating Cash Flow
$-62.4M
↑ 147.11%
Investing Cash Flow
$-263.6M
↑ 10779.61%
Financing Cash Flow
$257.9M
↓ 39.79%
FY23Y/Y Change
Operating Cash Flow
$-40.7M
↓ 34.72%
Investing Cash Flow
$-7.2M
↓ 97.26%
Financing Cash Flow
$3.2M
↓ 98.77%
Q2 FY23Q/Q Change
Operating Cash Flow
$-19.3M
↑ 653.69%
Investing Cash Flow
$-3.3M
↑ 36.18%
Financing Cash Flow
$4.5M
↑ 964.83%
Q3 FY23Q/Q Change
Operating Cash Flow
$-8.0M
↓ 58.32%
Investing Cash Flow
$-3.3M
↑ 0.0%
Financing Cash Flow
$641.0K
↓ 85.6%

Accolade Technicals Summary

Sell

Neutral

Buy

Accolade is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Accolade Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Accolade Inc
Accolade Inc
-5.43%
-43.78%
-66.79%
-85.57%
-88.28%
Solventum Corp
Solventum Corp
-0.04%
28.15%
1.32%
1.32%
1.32%
Doximity, Inc.
Doximity, Inc.
-0.3%
87.68%
98.34%
-5.4%
-0.57%
Veeva Systems Inc.
Veeva Systems Inc.
-0.3%
29.34%
28.68%
-11.76%
57.43%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
-3.03%
5.26%
8.83%
34.95%
34.95%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Accolade Inc
Accolade Inc
NA
NA
NA
-1.21
-0.19
-0.07
NA
5.26
Solventum Corp
Solventum Corp
NA
NA
NA
6.26
0.17
0.08
NA
NA
Doximity, Inc.
Doximity, Inc.
60.39
60.39
2.42
0.9
0.19
0.12
NA
5.15
Veeva Systems Inc.
Veeva Systems Inc.
57.74
57.74
1.3
4.76
0.13
0.06
NA
28.8
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
22.67
22.67
8.94
4.28
0.22
0.06
0.0
18.2
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Accolade Inc
Accolade Inc
Buy
$294.8M
-88.28%
NA
-18.16%
Solventum Corp
Solventum Corp
Hold
$10.8B
1.32%
NA
15.73%
Doximity, Inc.
Doximity, Inc.
Hold
$9.8B
-0.57%
60.39
33.69%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$38.0B
57.43%
57.74
23.91%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$37.8B
34.95%
22.67
8.56%

About Accolade

accolade is a personalized health and benefits solution that dramatically improves the experience, outcomes and cost of healthcare for employers, health plans and their members. with a unique blend of compassionate advisors, clinical experts and intelligent technologies, we engage individuals and families in their health, establish trust, and influence their decisions at every stage of care. we’ve been recognized as one of the nation’s 25 most promising companies by forbes magazine, the fastest-growing private healthcare company by inc. 500, and a top workplace by multiple news publications. for more information, visit www.accolade.com.
Organization
Accolade
Employees
2400
CEO
Mr. Rajeev Singh
Industry
Health Services

Management People of Accolade

NameTitle
Mr. Rajeev Singh
Chairman of the Board & CEO
Mr. Robert Cavanaugh
President
Mr. Stephen H. Barnes CPA
CFO & Treasurer
Mr. Richard Eskew J.D.
Executive VP, General Counsel, CCO & Secretary
Ms. Kristen Bruzek
Senior Vice President of Operations
Mr. Colin McHugh
Chief Accounting Officer
Mr. Todd Friedman
Senior Vice President of Investor Relations
Ms. Kelsi McDonald Harris
Chief People Officer & Senior Vice President
Mr. Drew Garner
Executive Vice President of Engineering
Dr. Shantanu Nundy M.B.A., M.D.
Executive VP, Chief Health Officer & Member of the Medical Advisory Board

Important FAQs about investing in Accolade from India :

What is Accolade share price today?

Accolade share price today stands at $3.49, Open: $3.47 ; Previous Close: $3.48 ; High: $3.52 ; Low: $3.41 ; 52 Week High: $15.36 ; 52 Week Low: $3.08. The stock opens at $3.47, after a previous close of $3.48. The stock reached a daily high of $3.52 and a low of $3.41, with a 52-week high of $15.36 and a 52-week low of $3.08.

Can Indians buy Accolade shares?

Yes, Indians can invest in the Accolade (ACCD) from India.

With INDmoney, you can buy Accolade at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Accolade at zero transaction cost.

How can I buy Accolade shares from India?

It is very easy to buy Accolade from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Accolade be purchased?

Yes, you can buy fractional shares of Accolade with INDmoney app.

What are the documents required to start investing in Accolade stocks?

To start investing in Accolade, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Accolade

Today’s highest price of Accolade (ACCD) is $3.52.

Today’s lowest price of Accolade (ACCD) is $3.41.

What is today's market capitalisation of Accolade

Today's market capitalisation of Accolade ACCD is 294.8M

What is the 52 Week High and Low Range of Accolade

  • 52 Week High

    $15.36

  • 52 Week Low

    $3.08

How much percentage Accolade is down from its 52 Week High?

Accolade (ACCD) share price is $3.49. It is down by 77.28% from its 52 Week High price of $15.36.

How much percentage Accolade is up from its 52 Week low?

Accolade (ACCD) share price is $3.49. It is up by 13.31% from its 52 Week Low price of $3.08.

What are the historical returns of Accolade?

  • 1 Month Returns

    -5.43%

  • 3 Months Returns

    -43.78%

  • 1 Year Returns

    -66.79%

  • 5 Years Returns

    -88.28%

Who is the Chief Executive Officer (CEO) of Accolade

Mr. Rajeev Singh is the current Chief Executive Officer (CEO) of Accolade.